1. The Bavarian Cell Therapy Catalyst
  2. Publications

Publications

Project 1-2.
Development of a chimeric antigen receptor that specifically and selectively recognizes acute myeloid leukemia (AML) blasts.Arming IPSC-derived NK cells with a CAR for treatment of AML

Stock S, Klüver AK, Fertig L, Menkhoff VD, Subklewe M, Endres S, Kobold S. Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control. Int J Cancer. 2023 Jun 23. https://onlinelibrary.wiley.com/doi/10.1002/ijc.34635

 

Märkl F , Schultheiß C , Murtaza A , Chen SS , Zintchenko M , Egli L , Mietz J , Chijioke O , Paschold L, Spajic S , Holtermann A , Dörr J , Stock S , Zingg A , Läubli H, Piseddu I , Anz D , Dühren-von Minden M , Zhang T , Nerreter T , Hudecek M , Minguet S , Chiorazzi N , Kobold S* , Binder M*: Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia. * co-corresponding. Nature Communications 2024 Feb 2;15(1):993. https://www.nature.com/articles/s41467-024-45378-w

Project 4. Development of NK cells as an alternative cell source for adoptive cell therapy

Yazdi M, Hasanzadeh Kafshgari M, Khademi Moghadam F, Zarezade V, Oellinger R, Khosravi M, Haas S, Hoch CC, Pockley AG, Wagner E, Wollenberg B, Multhoff G, Bashiri Dezfouli A. Crosstalk between NK cell receptors and tumor membrane Hsp70-derived peptide: A combined computational and experimental study. Adv Sci: 2305998, doi: 10.1002/advs.202305998, 2024. https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202305998


Lennartz P, Thölke D, Bashiri Dezfouli A, Pilz M, Lobinger D, Messner V, Zanth H, Ainslie K, Kafshgari MH, Rammes G, Ballmann M, Schlegel M, Foulds GA, Pockley AG, Schmidt-Graf F, Multhoff G. Biomarkers in adult-type diffuse gliomas: Elevated levels of circulating vesicular heat shock protein 70 serve as a biomarker in grade 4 glioblastoma and increase nk cell frequencies in grade 3 glioma. Biomedicines 11(12): 3235, doi: 10.3390/biomedicines11123235, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10741018/


Xanthopoulos A, Samt AK, Guder C, Taylor N, Roberts E, Herf H, Messner V, Trill A, Holzmann KLK, Kiechle M, Seifert-Klauss V, Zschaeck S, Schatka I, Tauber R, Schmidt R, Enste K, Pockley AG, Lobinger D, Multhoff G. Hsp70-A universal biomarker for predicting therapeutic failure in human female cancers and a target for CTC isolation in advanced cancers. Biomedicines 11(8): 2276, doi: 10.3390/biomedicines 11082276, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452093/


Safi S, Messner L, Kliebisch M, Eggert L, Ceylangil C, Lennartz P, Jefferies B, Klein H, Schirren M, Dommasch M, Lobinger D, Multhoff G. Circulating Hsp70 Levels and the immunophenotype of peripheral blood lymphocytes as potential biomarkers for advanced lung cancer and therapy failure after surgery. Biomolecules 13: 874, doi: 10.3390/biom13050874, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216400/